Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dr Reddys Laboratories (RDY) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to $454.4 million.

  • Dr Reddys Laboratories' Cost of Revenue rose 1108.53% to $454.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year increase of 1178.51%. This contributed to the annual value of $1.6 billion for FY2025, which is 1398.7% up from last year.
  • As of Q4 2025, Dr Reddys Laboratories' Cost of Revenue stood at $454.4 million, which was up 1108.53% from $436.5 million recorded in Q1 2025.
  • Dr Reddys Laboratories' 5-year Cost of Revenue high stood at $454.4 million for Q4 2025, and its period low was $312.0 million during Q2 2022.
  • In the last 5 years, Dr Reddys Laboratories' Cost of Revenue had a median value of $342.0 million in 2023 and averaged $354.8 million.
  • As far as peak fluctuations go, Dr Reddys Laboratories' Cost of Revenue crashed by 1357.34% in 2022, and later soared by 2351.49% in 2025.
  • Dr Reddys Laboratories' Cost of Revenue (Quarter) stood at $324.0 million in 2021, then grew by 1.54% to $329.0 million in 2022, then rose by 9.31% to $359.6 million in 2023, then grew by 13.73% to $409.0 million in 2024, then rose by 11.09% to $454.4 million in 2025.
  • Its last three reported values are $454.4 million in Q4 2025, $436.5 million for Q1 2025, and $409.0 million during Q4 2024.